UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...
Fierce Biotech1d
Character Biosciences lands $93M to lead pair of macular degeneration assets into the clinic
A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...
Clinical Trials Arena2d
Opthia could owe $1bn to investors amid sozinibercept trial failure
The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...
The Pharma Letter2d
Opthea’s future unclear after wet AMD failure
Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...
Endpoints News2d
Two biotechs fail to beat or match Re­gen­eron's Eylea in key tri­als
Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...
Fierce Biotech2d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...
pharmaphorum2d
Phase 3 readout puts Opthea at risk of insolvency
Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.